Ashland Inc. announces Benecel(TM) hypromellose controlled-release excipients for matrix tablets
(Thomson Reuters ONE) -
FOR IMMEDIATE RELEASE
Oct. 26, 2011
WILMINGTON, Del. - Ashland Specialty Ingredients, a commercial unit of Ashland
Inc. (NYSE: ASH), today announced three Benecel(TM) hypromellose (HPMC)
excipients are now available for the formulation of matrix tablets. These
commercial grades of intermediate-molecular-weight polymers deliver more
predictable controlled-release profiles than may be possible with blending
legacy grades of hypromellose. Benecel HPMC K250 PH PRM, HPMC K750 PH PRM and
HPMC K1500 PH PRM were developed to address predictability and consistency
issues stemming from blending practices and to provide formulators additional
choices to more easily achieve their desired release profile.
Hypromellose is the most widely used polymer in hydrophilic matrix systems, but
before Ashland's recent introduction, the number of commercially available
grades was limited. "Molecular weight plays a key role in dictating drug
release, so formulators choose specific molecular weight grades based on drug
solubility and desired release profile," said Divya Tewari, group leader,
Pharmaceutical R&D, Ashland Specialty Ingredients. "Our customers previously
often needed to blend two or more molecular weight grades to achieve the desired
target release profile for controlled-release tablets as actives and drugs
have become more complex. Blending can be problematic and costly. Predicting
release profiles from blending two different grades is not straightforward and
contributes greatly to batch-to-batch variability."
Tewari explained that the new grades eliminate the need for blending and offer
predictable and reproducible drug release profiles even under challenging
conditions such as in a full stomach, where hydrodynamic stresses are greater
and fat, bile, salt content and ionic strength vary significantly. "Our recent
research shows that under these dissolution conditions, controlled-release
tablets comprising blends of hypromellose have greater variability and, in some
cases, fail to control drug release as compared to formulated grades."
Delivering pharmaceutical and nutraceutical performance since the 1950s, Ashland
creates value for its customers through applications knowledge, regulatory
support and a powerful excipient portfolio:
* Advantia(TM) and Aquarius(TM) coating systems
* Aqualon(TM) ethylcellulose
* Aqualon(TM) and Blanose(TM) sodium carboxymethylcellulose
* Benecel(TM) methylcellulose and hypromellose
* Klucel(TM) hydroxypropylcellulose
* Natrosol(TM) hydroxyethylcellulose
* Plasdone(TM) copovidone
* Plasdone(TM) povidone
* Polyplasdone(TM) crospovidone
Ashland Specialty Ingredients offers industry-leading products, technologies and
resources for solving formulation and product performance challenges in key
markets including personal care, pharmaceutical, food and beverage, coatings and
energy. Using natural, synthetic and semi-synthetic polymers derived from plant
and seed extract, cellulose ethers and vinyl pyrrolidones, Ashland Specialty
Ingredients offers comprehensive and innovative solutions for today's demanding
consumer and industrial applications.
In more than 100 countries, the people of Ashland Inc. (NYSE: ASH) provide the
specialty chemicals, technologies and insights to help customers create new and
improved products for today and sustainable solutions for tomorrow. Our
chemistry is at work every day in a wide variety of markets and applications,
including architectural coatings, automotive, construction, energy, food and
beverage, personal care, pharmaceutical, tissue and towel, and water treatment.
Visit www.ashland.com to see the innovations we offer through our four
commercial units - Ashland Specialty Ingredients, Ashland Water Technologies,
Ashland Performance Materials and Ashland Consumer Markets (Valvoline).
- 0 -
(TM)Trademark of Ashland or its subsidiaries, registered in various countries
FOR FURTHER INFORMATION:
Richard R. Ruberti Sr.
+1 302-594-6850
rrruberti(at)ashland.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ashland Inc. via Thomson Reuters ONE
[HUG#1557876]
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2011 - 10:05 Uhr
Sprache: Deutsch
News-ID 80280
Anzahl Zeichen: 5056
contact information:
Town:
Covington
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ashland Inc. announces Benecel(TM) hypromellose controlled-release excipients for matrix tablets"
steht unter der journalistisch-redaktionellen Verantwortung von
Ashland Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
